Fibronectin 1 promotes migration and invasion of papillary thyroid cancer and predicts papillary thyroid cancer lymph node metastasis

Abstract

Lymph node metastasis (LNM) is common in papillary thyroid cancer (PTC), and is an indicator of recurrence. The detailed molecular mechanism of LNM in PTC has not been well described. This study aimed to investigate the role of fibronectin 1 in PTC LNM and its clinical relevance. The expression of fibronectin 1 was confirmed in PTC tissues and cell lines. A correlation analysis was conducted and a receiver-operating characteristic curve obtained. The effect of fibronectin 1 on the proliferation of PTC cell lines was performed using a colony-formation assay and Cell Counting Kit 8. Cell-cycle analysis was performed with a flow-cytometry assay. Migration and invasion ability were evaluated by transwell and wound-healing assays. Fibronectin 1 was overexpressed in metastasized PTC. Overexpressed fibronectin 1 was positively correlated with PTC LNM. Receiver-operating characteristic analysis showed that the diagnostic accuracy of fibronectin 1 was 81.1%, with sensitivity of 80% and specificity of 82%. Overexpression of fibronectin 1 promoted proliferation, migration, and invasion in PTC. Fibronectin 1 plays a critical role in PTC metastasis by modulating the proliferation, migration, and invasion ability of PTC cells, and it is a valuable diagnostic biomarker for predicting PTC LNM.

RETRACTED ARTICLE: Downregulation of NEAT1 reverses the radioactive iodine resistance of papillary thyroid carcinoma cell via miR-101-3p/FN1/PI3K-AKT signaling pathway

“…MiR-101-3p has been found to be sponged by lncRNA-MALAT1 and therefore resulted in decreased apoptosis rate of cisplatinresistant lung cells [10]. Another study proposed that NEAT1 inhibited the expression of miR-101-3p and reversed irradiation-resistance in nasopharyngeal carcinoma, which was similar to our study [11]. There are no studies that have been published on the effects of miR-101-3p on RAI resistance of PTC.…”

“…FN1 was demonstrated as a promising target of miR-101-3p. A previous study revealed that FN1 promoted cell EMT and chemoresistance in breast cancer [11], implying its role in enhancing chemoresistance. In the study, we discovered that the expression level of FN1 was enhanced by miR-101-3p deficiency, which therefore promoted the RAI-resistance of PTC.…”

“…Fibronectin 1 (FN1), a basic component of the extracellular matrix, is one of the biomarkers in epithelial-mesenchymal transition (EMT), which is a vital process in cancer progression [11]. Urine fibronectin is reported as a non-invasive diagnostic biomarker in bladder cancer patients.…”

Aging‑associated genes TNFRSF12A and CHI3L1 contribute to thyroid cancer: An evidence for the involvement of hypoxia as a driver

“…TIMP-1, acts as an inhibitor for MMP9 expression that is often co-expressed with this molecule in thyroid tumors and serves as a reliable surrogate marker for BRAF-mutated status and likely aggressiveness (41). Notably, TIMP-1 serves as a prominent PPI hub gene in the Cytoscape network built upon co-expression of TNFRSF12A and CHI3L1, along with LGALS3, a specific biomarker of well-differentiated thyroid carcinomas (42), CXCL16, which mediated the involvement of macrophages in the invasion of papillary TCs (43) and fibronectin, an EMT biomarker which promoted migration and invasion of papillary thyroid cancers (44).…”

Identification of glutathione S‑transferase π 1 as a prognostic proteomic biomarker for multiple myeloma using proteomic profiling

“…It has been reported that FN1 is upregulated in several tumors such as nasopharyngeal carcinoma (31) and melanoma (32). Upregulation of FN1 indicates poor prognosis in thyroid cancer and nasopharyngeal cancer (33,34). A previous study demonstrated that FN1 may be a potential biomarker for radiotherapy and drug resistance in head and neck squamous cell carcinoma (35).…”